

Amit S Kalgutkar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2251496/publications.pdf>

Version: 2024-02-01

102
papers

7,424
citations

81900

39
h-index

56724

83
g-index

115
all docs

115
docs citations

115
times ranked

7037
citing authors

#	ARTICLE	IF	CITATIONS
1	An oral SARS-CoV-2 M ^{pro} inhibitor clinical candidate for the treatment of COVID-19. <i>Science</i> , 2021, 374, 1586-1593.	12.6	1,074
2	A Comprehensive Listing of Bioactivation Pathways of Organic Functional Groups. <i>Current Drug Metabolism</i> , 2005, 6, 161-225.	1.2	592
3	Structural Alert/Reactive Metabolite Concept as Applied in Medicinal Chemistry to Mitigate the Risk of Idiosyncratic Drug Toxicity: A Perspective Based on the Critical Examination of Trends in the Top 200 Drugs Marketed in the United States. <i>Chemical Research in Toxicology</i> , 2011, 24, 1345-1410.	3.3	569
4	Biotransformation Reactions of Five-Membered Aromatic Heterocyclic Rings. <i>Chemical Research in Toxicology</i> , 2002, 15, 269-299.	3.3	471
5	Mechanism-Based Inactivation of Cytochrome P450 Enzymes: Chemical Mechanisms, Structure-Activity Relationships and Relationship to Clinical Drug-Drug Interactions and Idiosyncratic Adverse Drug Reactions. <i>Current Drug Metabolism</i> , 2007, 8, 407-447.	1.2	238
6	Interactions of Nitrogen-Containing Xenobiotics with Monoamine Oxidase (MAO) Isozymes A and B: SAR Studies on MAO Substrates and Inhibitors. <i>Chemical Research in Toxicology</i> , 2001, 14, 1139-1162.	3.3	198
7	Minimising the potential for metabolic activation in drug discovery. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2005, 1, 91-142.	3.3	198
8	Can In Vitro Metabolism-Dependent Covalent Binding Data in Liver Microsomes Distinguish Hepatotoxic from Nonhepatotoxic Drugs? An Analysis of 18 Drugs with Consideration of Intrinsic Clearance and Daily Dose. <i>Chemical Research in Toxicology</i> , 2008, 21, 1814-1822.	3.3	194
9	Mechanism-Based Inactivation (MBI) of Cytochrome P450 Enzymes: Structure-Activity Relationships and Discovery Strategies To Mitigate Drug-Drug Interaction Risks. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 4896-4933.	6.4	176
10	BIOACTIVATION OF THE NONTRICYCLIC ANTIDEPRESSANT NEFAZODONE TO A REACTIVE QUINONE-IMINE SPECIES IN HUMAN LIVER MICROSOMES AND RECOMBINANT CYTOCHROME P450 3A4. <i>Drug Metabolism and Disposition</i> , 2005, 33, 243-253.	3.3	160
11	Drug discovery for a new generation of covalent drugs. <i>Expert Opinion on Drug Discovery</i> , 2012, 7, 561-581.	5.0	140
12	Can In Vitro Metabolism-Dependent Covalent Binding Data Distinguish Hepatotoxic from Nonhepatotoxic Drugs? An Analysis Using Human Hepatocytes and Liver S-9 Fraction. <i>Chemical Research in Toxicology</i> , 2009, 22, 332-340.	3.3	127
13	Inhibition of Hepatobiliary Transport as a Predictive Method for Clinical Hepatotoxicity of Nefazodone. <i>Toxicological Sciences</i> , 2006, 90, 451-459.	3.1	122
14	Application of a linear ion trap/orbitrap mass spectrometer in metabolite characterization studies: Examination of the human liver microsomal metabolism of the non-tricyclic anti-depressant nefazodone using data-dependent accurate mass measurements. <i>Journal of the American Society for Mass Spectrometry</i> , 2006, 17, 363-375.	2.8	113
15	Discovery of a Clinical Candidate from the Structurally Unique Dioxo-bicyclo[3.2.1]octane Class of Sodium-Dependent Glucose Cotransporter 2 Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 2952-2960.	6.4	112
16	Pharmacokinetics, Metabolism, and Excretion of the Antidiabetic Agent Ertugliflozin (PF-04971729) in Healthy Male Subjects. <i>Drug Metabolism and Disposition</i> , 2013, 41, 445-456.	3.3	107
17	On the Diversity of Oxidative Bioactivation Reactions on Nitrogen-Containing Xenobiotics. <i>Current Drug Metabolism</i> , 2002, 3, 379-424.	1.2	103
18	In Vitro Metabolism and Covalent Binding of Enol-Carboxamide Derivatives and Anti-Inflammatory Agents Sudoxicam and Meloxicam: Insights into the Hepatotoxicity of Sudoxicam. <i>Chemical Research in Toxicology</i> , 2008, 21, 1890-1899.	3.3	102

#	ARTICLE	IF	CITATIONS
19	Metabolic activation in drug-induced liver injury. <i>Drug Metabolism Reviews</i> , 2012, 44, 18-33.	3.6	101
20	Activation of Liver AMPK with PF-06409577 Corrects NAFLD and Lowers Cholesterol in Rodent and Primate Preclinical Models. <i>EBioMedicine</i> , 2018, 31, 122-132.	6.1	99
21	A Semiquantitative Method for the Determination of Reactive Metabolite Conjugate Levels in Vitro Utilizing Liquid Chromatography-Tandem Mass Spectrometry and Novel Quaternary Ammonium Glutathione Analogues. <i>Chemical Research in Toxicology</i> , 2006, 19, 480-490.	3.3	98
22	Discovery and Preclinical Characterization of 6-Chloro-5-[4-(1-hydroxycyclobutyl)phenyl]-1 <i>H</i> -indole-3-carboxylic Acid (PF-06409577), a Direct Activator of Adenosine Monophosphate-activated Protein Kinase (AMPK), for the Potential Treatment of Diabetic Nephropathy. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 8068-8081.	6.4	98
23	MECHANISM-BASED INACTIVATION OF HUMAN RECOMBINANT P450 2C9 BY THE NONSTEROIDAL ANTI-INFLAMMATORY DRUG SUPROFEN. <i>Drug Metabolism and Disposition</i> , 2003, 31, 1369-1377.	3.3	92
24	Predicting Toxicities of Reactive Metabolite-Positive Drug Candidates. <i>Annual Review of Pharmacology and Toxicology</i> , 2015, 55, 35-54.	9.4	91
25	Selective inhibitors of monoamine oxidase (MAO-A and MAO-B) as probes of its catalytic site and mechanism. <i>Medicinal Research Reviews</i> , 1995, 15, 325-388.	10.5	90
26	Designing around Structural Alerts in Drug Discovery. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 6276-6302.	6.4	90
27	Structural Alerts, Reactive Metabolites, and Protein Covalent Binding: How Reliable Are These Attributes as Predictors of Drug Toxicity?. <i>Chemistry and Biodiversity</i> , 2009, 6, 2115-2137.	2.1	87
28	Metabolism-guided drug design. <i>MedChemComm</i> , 2013, 4, 631.	3.4	84
29	NADPH-Dependent Covalent Binding of [³ H]Paroxetine to Human Liver Microsomes and S-9 Fractions: Identification of an Electrophilic Quinone Metabolite of Paroxetine. <i>Chemical Research in Toxicology</i> , 2007, 20, 1649-1657.	3.3	80
30	Comparison of the Bioactivation Potential of the Antidepressant and Hepatotoxin Nefazodone with Aripiprazole, a Structural Analog and Marketed Drug. <i>Drug Metabolism and Disposition</i> , 2008, 36, 1016-1029.	3.3	78
31	Selective Activation of AMPK ¹ -Containing Isoforms Improves Kidney Function in a Rat Model of Diabetic Nephropathy. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2017, 361, 303-311.	2.5	66
32	Disposition of Nirmatrelvir, an Orally Bioavailable Inhibitor of SARS-CoV-2 3C-Like Protease, across Animals and Humans. <i>Drug Metabolism and Disposition</i> , 2022, 50, 576-590.	3.3	64
33	Preclinical Species and Human Disposition of PF-04971729, a Selective Inhibitor of the Sodium-Dependent Glucose Cotransporter 2 and Clinical Candidate for the Treatment of Type 2 Diabetes Mellitus. <i>Drug Metabolism and Disposition</i> , 2011, 39, 1609-1619.	3.3	63
34	Genotoxicity of 2-(3-Chlorobenzyloxy)-6-(piperazinyl)pyrazine, a Novel 5-Hydroxytryptamine _{2c} Receptor Agonist for the Treatment of Obesity: Role of Metabolic Activation. <i>Drug Metabolism and Disposition</i> , 2007, 35, 848-858.	3.3	53
35	A Rational Chemical Intervention Strategy To Circumvent Bioactivation Liabilities Associated with a Nonpeptidyl Thrombopoietin Receptor Agonist Containing a 2-Amino-4-arylthiazole Motif. <i>Chemical Research in Toxicology</i> , 2007, 20, 1954-1965.	3.3	52
36	Metabolic activation of the nontricyclic antidepressant trazodone to electrophilic quinone-imine and epoxide intermediates in human liver microsomes and recombinant P4503A4. <i>Chemico-Biological Interactions</i> , 2005, 155, 10-20.	4.0	51

#	ARTICLE	IF	CITATIONS
37	Trifluoromethylpyrimidine-based inhibitors of proline-rich tyrosine kinase 2 (PYK2): Structure-activity relationships and strategies for the elimination of reactive metabolite formation. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 6071-6077.	2.2	50
38	Discovery of 2-(6-(5-Chloro-2-methoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2 <i>H</i>)-yl)acetamide (PF-06282999): A Highly Selective Mechanism-Based Myeloperoxidase Inhibitor for the Treatment of Cardiovascular Diseases. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 8513-8528.	6.4	46
39	Establishing Transcriptional Signatures to Differentiate PXR-, CAR-, and AhR-Mediated Regulation of Drug Metabolism and Transport Genes in Cryopreserved Human Hepatocytes. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018, 365, 262-271.	2.5	46
40	Discovery of PF-06835919: A Potent Inhibitor of Ketohexokinase (KHK) for the Treatment of Metabolic Disorders Driven by the Overconsumption of Fructose. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 13546-13560.	6.4	43
41	A Small-Molecule Oral Agonist of the Human Glucagon-like Peptide-1 Receptor. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 8208-8226.	6.4	42
42	Practical and Science-Based Strategy for Establishing Acceptable Intakes for Drug Product <i>N</i> -Nitrosamine Impurities. <i>Chemical Research in Toxicology</i> , 2022, 35, 475-489.	3.3	36
43	Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38 β inhibitor: identification of an active metabolite in preclinical species and human liver microsomes. <i>Biopharmaceutics and Drug Disposition</i> , 2006, 27, 371-386.	1.9	34
44	The discovery of novel calcium sensing receptor negative allosteric modulators. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 3328-3332.	2.2	34
45	Practical approaches to resolving reactive metabolite liabilities in early discovery. <i>Drug Metabolism Reviews</i> , 2015, 47, 56-70.	3.6	32
46	Myeloperoxidase inhibition in mice alters atherosclerotic lesion composition. <i>PLoS ONE</i> , 2019, 14, e0214150.	2.5	30
47	Toxicophores, reactive metabolites and drug safety: when is it a cause for concern?. <i>Expert Review of Clinical Pharmacology</i> , 2008, 1, 515-531.	3.1	29
48	On the importance of synthetic organic chemistry in drug discovery: reflections on the discovery of antidiabetic agent ertugliflozin. <i>MedChemComm</i> , 2013, 4, 101-111.	3.4	29
49	In Vitro Metabolism of the Glucagon-Like Peptide-1 (GLP-1)-Derived Metabolites GLP-1(9-36)amide and GLP-1(28-36)amide in Mouse and Human Hepatocytes. <i>Drug Metabolism and Disposition</i> , 2013, 41, 2148-2157.	3.3	29
50	Design and evaluation of a 2-(2,3,6-trifluorophenyl)acetamide derivative as an agonist of the GPR119 receptor. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 1306-1309.	2.2	27
51	Simulation of human plasma concentration-time profiles of the partial glucokinase activator PF-04937319 and its disproportionate N-demethylated metabolite using humanized chimeric mice and semi-physiological pharmacokinetic modeling. <i>Xenobiotica</i> , 2017, 47, 382-393.	1.1	26
52	Biochemical basis for differences in metabolism-dependent genotoxicity by two diazinylpiperazine-based 5-HT _{2C} receptor agonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 1559-1563.	2.2	25
53	Pharmacokinetics and Disposition of the Thiouracil Derivative PF-06282999, an Orally Bioavailable, Irreversible Inactivator of Myeloperoxidase Enzyme, Across Animals and Humans. <i>Drug Metabolism and Disposition</i> , 2016, 44, 209-219.	3.3	25
54	Effective Application of Metabolite Profiling in Drug Design and Discovery. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 6387-6406.	6.4	25

#	ARTICLE	IF	CITATIONS
55	N-(3,4-dimethoxyphenethyl)-4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2[1H]-yl)-6,7-dimethoxyquinazolin-2-amine (CP-100,356) as a chemical knock-out equivalent to assess the impact of efflux transporters on oral drug absorption in the rat. <i>Journal of Pharmaceutical Sciences</i> , 2009, 98, 4914-4927.	3.3	24
56	Discovery Tactics To Mitigate Toxicity Risks Due to Reactive Metabolite Formation with 2-(2-Hydroxyaryl)-5-(trifluoromethyl)pyrido[4,3-d]pyrimidin-4(3H)-one Derivatives, Potent Calcium-Sensing Receptor Antagonists and Clinical Candidate(s) for the Treatment of Osteoporosis. <i>Chemical Research in Toxicology</i> , 2010, 23, 1115-1126.	3.3	24
57	Liabilities Associated with the Formation of Hard Electrophiles in Reactive Metabolite Trapping Screens. <i>Chemical Research in Toxicology</i> , 2017, 30, 220-238.	3.3	24
58	Role of Transporters in the Disposition of the Selective Phosphodiesterase-4 Inhibitor (+)-2-[4-({[2-(Benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic Acid in Rat and Human. <i>Drug Metabolism and Disposition</i> , 2007, 35, 2111-2118.	3.3	23
59	Short-acting 5-(trifluoromethyl)pyrido[4,3-d]pyrimidin-4(3H)-one derivatives as orally-active calcium-sensing receptor antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 4555-4559.	2.2	23
60	Oxidative Metabolism of a Quinoxaline Derivative by Xanthine Oxidase in Rodent Plasma. <i>Chemical Research in Toxicology</i> , 2011, 24, 2207-2216.	3.3	22
61	From partial to full agonism: Identification of a novel 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole as a full agonist of the human GPR119 receptor. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 194-197.	2.2	22
62	Nicotinic acid transport into human liver involves organic anion transporter 2 (SLC22A7). <i>Biochemical Pharmacology</i> , 2020, 174, 113829.	4.4	22
63	Intrinsic electrophilicity of the 4-methylsulfonyl-2-pyridone scaffold in glucokinase activators: Role of glutathione-S-transferases and in vivo quantitation of a glutathione conjugate in rats. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 6262-6267.	2.2	21
64	Identification of an N-methyl-4-phenylpyridinium-like metabolite of the antidiarrheal agent loperamide in human liver microsomes: underlying reason(s) for the lack of neurotoxicity despite the bioactivation event. <i>Drug Metabolism and Disposition</i> , 2004, 32, 943-52.	3.3	21
65	Demonstration of the Innate Electrophilicity of 4-(3-(Benzyloxy)phenyl)-2-(ethylsulfinyl)-6-(trifluoromethyl)pyrimidine (BETP), a Small-Molecule Positive Allosteric Modulator of the Glucagon-Like Peptide-1 Receptor. <i>Drug Metabolism and Disposition</i> , 2013, 41, 1470-1479.	3.3	20
66	The Antimicrobial Agent Fusidic Acid Inhibits Organic Anion Transporting Polypeptide-Mediated Hepatic Clearance and May Potentiate Statin-Induced Myopathy. <i>Drug Metabolism and Disposition</i> , 2016, 44, 692-699.	3.3	20
67	Structural attributes influencing unbound tissue distribution. <i>European Journal of Medicinal Chemistry</i> , 2020, 185, 111813.	5.5	19
68	Optimizing the Benefit/Risk of Acetyl-CoA Carboxylase Inhibitors through Liver Targeting. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 10879-10896.	6.4	19
69	Intrinsic Electrophilicity of a 4-Substituted-5-cyano-6-(2-methylpyridin-3-yloxy)pyrimidine Derivative: Structural Characterization of Glutathione Conjugates in Vitro. <i>Chemical Research in Toxicology</i> , 2011, 24, 269-278.	3.3	18
70	Metabolites in Safety Testing Assessment in Early Clinical Development: A Case Study with a Glucokinase Activator. <i>Drug Metabolism and Disposition</i> , 2014, 42, 1926-1939.	3.3	18
71	Acyl Glucuronide Metabolites of 6-Chloro-5-[4-(1-hydroxycyclobutyl)phenyl]-1 <i>H</i> -indole-3-carboxylic Acid (PF-06409577) and Related Indole-3-carboxylic Acid Derivatives are Direct Activators of Adenosine Monophosphate-Activated Protein Kinase (AMPK). <i>Journal of Medicinal Chemistry</i> , 2018, 61, 7273-7288.	6.4	18
72	Handling reactive metabolite positives in drug discovery: What has retrospective structure-toxicity analyses taught us?. <i>Chemico-Biological Interactions</i> , 2011, 192, 46-55.	4.0	17

#	ARTICLE	IF	CITATIONS
73	Comparison of the Circulating Metabolite Profile of PF-04991532, a Hepatoselective Glucokinase Activator, Across Preclinical Species and Humans: Potential Implications in Metabolites in Safety Testing Assessment. <i>Drug Metabolism and Disposition</i> , 2015, 43, 190-198.	3.3	14
74	Examination of the Human Cytochrome P4503A4 Induction Potential of PF-06282999, an Irreversible Myeloperoxidase Inactivator: Integration of Preclinical, In Silico, and Biomarker Methodologies in the Prediction of the Clinical Outcome. <i>Drug Metabolism and Disposition</i> , 2017, 45, 501-511.	3.3	14
75	Predicting the Human Hepatic Clearance of Acidic and Zwitterionic Drugs. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 11831-11844.	6.4	14
76	Optimization of Metabolic and Renal Clearance in a Series of Indole Acid Direct Activators of 5'-Adenosine Monophosphate-Activated Protein Kinase (AMPK). <i>Journal of Medicinal Chemistry</i> , 2018, 61, 2372-2383.	6.4	13
77	Organic Anion-Transporting Polypeptide 1B1/1B3-Mediated Hepatic Uptake Determines the Pharmacokinetics of Large Lipophilic Acids: In Vitro-In Vivo Evaluation in Cynomolgus Monkey. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2021, 377, 169-180.	2.5	12
78	Differences in CYP3A4 catalyzed bioactivation of 5-aminooxindole and 5-aminobenzosultam scaffolds in proline-rich tyrosine kinase 2 (PYK2) inhibitors: Retrospective analysis by CYP3A4 molecular docking, quantum chemical calculations and glutathione adduct detection using linear ion trap/orbitrap mass spectrometry. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 3177-3182.	2.2	11
79	Is there enough evidence to classify cycloalkyl amine substituents as structural alerts?. <i>Biochemical Pharmacology</i> , 2020, 174, 113796.	4.4	11
80	Inhibition of Hepatobiliary Transport Activity by the Antibacterial Agent Fusidic Acid: Insights into Factors Contributing to Conjugated Hyperbilirubinemia/Cholestasis. <i>Chemical Research in Toxicology</i> , 2016, 29, 1778-1788.	3.3	10
81	Pharmacodynamic Model of Parathyroid Hormone Modulation by a Negative Allosteric Modulator of the Calcium-Sensing Receptor. <i>AAPS Journal</i> , 2011, 13, 265-273.	4.4	9
82	Comprehensive Nonclinical Safety Assessment of Nirmatrelvir Supporting Timely Development of the SARS-COV-2 Antiviral Therapeutic, Paxlovid,®. <i>International Journal of Toxicology</i> , 2022, 41, 276-290.	1.2	9
83	Elucidation of the biochemical basis for a clinical drug-drug interaction between atorvastatin and 5-(4-(4-ethylbenzyl)thio)phenyl)sulfamoyl-2-methyl benzoic acid (CP-778875), a subtype selective agonist of the peroxisome proliferator-activated receptor alpha. <i>Xenobiotica</i> , 2013, 43, 963-972.	1.1	8
84	Induction of human cytochrome P450 3A4 by the irreversible myeloperoxidase inactivator PF-06282999 is mediated by the pregnane X receptor. <i>Xenobiotica</i> , 2018, 48, 647-655.	1.1	8
85	Future of Biotransformation Science in the Pharmaceutical Industry. <i>Drug Metabolism and Disposition</i> , 2022, 50, 258-267.	3.3	8
86	Role of Bioactivation in Idiosyncratic Drug Toxicity: Structure-Toxicity Relationships. , 2008, , 1-29.		7
87	Reactive Metabolite Trapping Studies on Imidazo- and 2-Methylimidazo[2,1-b]thiazole-Based Inverse Agonists of the Ghrelin Receptor. <i>Drug Metabolism and Disposition</i> , 2013, 41, 1375-1388.	3.3	7
88	Species Differences in the Oxidative Desulfurization of a Thiouracil-Based Irreversible Myeloperoxidase Inactivator by Flavin-Containing Monooxygenase Enzymes. <i>Drug Metabolism and Disposition</i> , 2016, 44, 1262-1269.	3.3	6
89	Optimization of amide-based EP3 receptor antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 2670-2675.	2.2	6
90	Pharmacokinetics and metabolism studies on the glucagon-like peptide-1 (GLP-1)-derived metabolite GLP-1(9-36)amide in male Beagle dogs. <i>Xenobiotica</i> , 2014, 44, 842-848.	1.1	4

#	ARTICLE	IF	CITATIONS
91	Identification of a novel, non-tetrahydroquinoline variant of the cholesteryl ester transfer protein (CETP) inhibitor torcetrapib, with improved aqueous solubility. <i>Xenobiotica</i> , 2014, 44, 591-605.	1.1	4
92	A sensitive method for the quantitation of the peptide-based glucagon-like peptide-1 receptor agonist liraglutide in plasma using microfluidics chromatography tandem MS. <i>Bioanalysis</i> , 2018, 10, 357-368.	1.5	4
93	Novel advances in biotransformation and bioactivation research â€“ 2020 year in review. <i>Drug Metabolism Reviews</i> , 2021, 53, 384-433.	3.6	4
94	Biotransformation novel advances â€“ 2021 year in review. <i>Drug Metabolism Reviews</i> , 2022, 54, 207-245.	3.6	3
95	Transporter-Enzyme Interplay in the Pharmacokinetics of PF-06835919, a First-In-Class Ketoheokinase Inhibitor for Metabolic Disorders and Nonalcoholic Fatty Liver Disease. <i>Drug Metabolism and Disposition</i> , 2022, 50, 1312-1321.	3.3	3
96	The Role of Biotransformation Studies in Reducing Drug Attrition. <i>Topics in Medicinal Chemistry</i> , 2013, , 97-137.	0.8	2
97	6-Chloro-5-[4-(1-Hydroxycyclobutyl)Phenyl]-1 <i>H</i> -Indole-3-Carboxylic Acid is a Highly Selective Substrate for Glucuronidation by UGT1A1, Relative to ¹² -Estradiol. <i>Drug Metabolism and Disposition</i> , 2018, 46, 1836-1846.	3.3	2
98	Metabolism and excretion of (PF-04991532), a hepatoselective glucokinase activator, in humans: confirmation of the MIST potential noted in first-in-Human metabolite scouting studies. <i>Xenobiotica</i> , 2019, 49, 1447-1457.	1.1	2
99	Reliability of reactive metabolite and covalent binding assessments in prediction of idiosyncratic drug toxicity. , 0, , 102-123.		1
100	Pharmacokinetics, Mass Balance, Metabolism, and Excretion of the Liver-Targeted Acetyl-CoA Carboxylase Inhibitor PF-05221304 (Clesacostat) in Humans. <i>Xenobiotica</i> , 2022, , 1-45.	1.1	1
101	The 2 nd Alpine Winter Conference on Medicinal and Synthetic Chemistry. <i>ChemMedChem</i> , 2021, 16, 2417-2423.	3.2	0
102	Chemical Research in Toxicology at 35: Recognizing the Impact of Professor Larry Marnett. <i>Chemical Research in Toxicology</i> , 2022, , .	3.3	0